Previous studies have consistently shown that GrB+ B cells possess anti-tumor function, indicating that patients with lower percentages of GrB+ B cells are more susceptible to recurrence or disease progression [8, 15, 21]. The gene discussed is GZMB; the disease is neoplasm.